Travere Therapeutics Inc. Insider Trading

TVTX

Last 12 months

Insiders sold $110M and bought nothing on the open market.

99% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jun 2017.

Net open-market

−$110M

0 buys · 57 sales

Under a 10b5-1 plan

99%

of the value sold

Insiders who bought / sold

0 / 11

executives and directors

Last open-market buy

Jun 2017

Jun 14, 2017

Get an email when TVTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 15	Eric M Dube Chief Executive Officer	Sold10b5-1 plan 3 parts	243,735	$53.82 average	$13.1M	36%	Form 4
Sep 15 – 17	Peter Heerma EVP, Chief Commercial Officer	Sold10b5-1 plan 7 parts	283,189	$63.06 average	$17.9M	71%	Form 4
Sep 15 – 17	Eric M Dube Chief Executive Officer	Sold10b5-1 plan 8 parts	400,000	$63.48 average	$25.4M	48%	Form 4
Sep 15 – 16	William E. Rote Chief Research Officer	Sold10b5-1 plan 6 parts	209,048	$62.83 average	$13.1M	68%	Form 4
Sep 15	Christopher R. Cline Chief Financial Officer	Sold10b5-1 plan 4 parts	50,508	$62.34 average	$3.15M	37%	Form 4
Sep 15	Jula Inrig EVP, Head of R&D & CMO	Sold10b5-1 plan 4 parts	44,674	$62.34 average	$2.79M	31%	Form 4
Sep 15	Sandra Calvin SVP, Chief Accounting Officer	Sold10b5-1 plan 3 parts	5,375	$62.33 average	335K	11%	Form 4
Sep 15	Elizabeth E Reed Chief Legal Officer and GC	Sold10b5-1 plan 4 parts	37,500	$62.34 average	$2.34M	26%	Form 4
Sep 10	Jeffrey A Meckler Director	Sold10b5-1 plan 4 parts	20,000	$67.30 average	$1.35M	18%	Form 4
Sep 2	Christopher R. Cline Chief Financial Officer	SoldNo plan	642	$66.37	43K	0.5%	Form 4
Aug 17 – 18	Gary A Lyons Director	Sold10b5-1 plan 5 parts	10,000	$63.29 average	633K	14%	Form 4
Jun 12	Roy D. Baynes Director	Sold10b5-1 plan	4,500	$50.00	225K	9.8%	Form 4
Jun 12	Timothy Coughlin Director	Sold10b5-1 plan	10,000	$50.07	501K	15%	Form 4
May 15	Timothy Coughlin Director	Sold10b5-1 plan	3,250	$43.49	141K	5.9%	Form 4
May 5 – 6	Christopher R. Cline Chief Financial Officer	Sold10b5-1 plan 2 parts	2,491	$46.31 average	115K	2.1%	Form 4
May 4 – 6	Jula Inrig Chief Medical Officer	Sold10b5-1 plan 3 parts	22,485	$45.15 average	$1.02M	17%	Form 4
May 6	Eric M Dube Chief Executive Officer	Sold10b5-1 plan	22,500	$43.95	989K	4.9%	Form 4
May 6	William E. Rote Chief Research Officer	Sold10b5-1 plan	2,763	$43.95	121K	2.3%	Form 4
May 4 – 6	Elizabeth E Reed Chief Legal Officer and GC	Sold10b5-1 plan 3 parts	24,250	$45.06 average	$1.09M	19%	Form 4
May 5	Peter Heerma Chief Commercial Officer	SoldNo plan	2,174	$46.65	101K	1.5%	Form 4
May 5	Roy D. Baynes Director	Sold10b5-1 plan	4,500	$46.65	210K	11%	Form 4
May 4	Jeffrey A Meckler Director	Sold10b5-1 plan	8,000	$45.00	360K	8.4%	Form 4
May 1	Roy D. Baynes Director	Sold10b5-1 plan	9,750	$44.22	431K	21%	Form 4
Apr 22	William E. Rote Chief Research Officer	Sold10b5-1 plan	9,100	$39.09	356K	7.4%	Form 4
Apr 13 – 15	Christopher R. Cline Chief Financial Officer	Sold10b5-1 plan 4 parts	8,327	$41.91 average	349K	6.6%	Form 4
Apr 14 – 15	Jula Inrig Chief Medical Officer	Sold10b5-1 plan 2 parts	8,233	$42.01 average	346K	6.9%	Form 4
Apr 15	Eric M Dube Chief Executive Officer	Sold10b5-1 plan 3 parts	64,000	$41.09 average	$2.63M	13%	Form 4
Apr 14 – 15	Elizabeth E Reed Chief Legal Officer and GC	Sold10b5-1 plan 4 parts	51,500	$41.29 average	$2.13M	33%	Form 4
Apr 14	Sandra Calvin SVP, Chief Accounting Officer	Sold10b5-1 plan	21,977	$41.07	903K	34%	Form 4
Apr 14	Roy D. Baynes Director	Sold10b5-1 plan 2 parts	32,750	$41.29 average	$1.35M	47%	Form 4
Apr 14	Gary A Lyons Director	Sold10b5-1 plan	8,000	$41.07	329K	12%	Form 4
Apr 14	Peter Heerma Chief Commercial Officer	SoldNo plan	7,215	$41.93	303K	4.9%	Form 4
Apr 6	Roy D. Baynes Director	Sold10b5-1 plan	10,000	$33.00	330K	21%	Form 4
Apr 1	Eric M Dube Chief Executive Officer	Sold10b5-1 plan 2 parts	60,000	$30.93 average	$1.86M	12%	Form 4
Apr 1	Elizabeth E Reed Chief Legal Officer and GC	Sold10b5-1 plan	10,000	$30.00	300K	8.7%	Form 4
Mar 16	Elizabeth E Reed Chief Legal Officer and GC	Sold10b5-1 plan	10,000	$28.09	281K	8.7%	Form 4
Feb 20	Eric M Dube Chief Executive Officer	Sold10b5-1 plan	60,000	$30.10	$1.81M	12%	Form 4
Feb 17	Elizabeth E Reed Chief Legal Officer and GC	Sold10b5-1 plan 2 parts	10,000	$27.83 average	278K	8.7%	Form 4
Feb 4	Christopher R. Cline Chief Financial Officer	Sold10b5-1 plan 2 parts	1,745	$32.19 average	56K	1.5%	Form 4
Feb 4	Jula Inrig Chief Medical Officer	Sold10b5-1 plan 2 parts	1,779	$32.21 average	57K	1.7%	Form 4

Oct 1510b5-1 plan
Eric M Dube
Chief Executive Officer · sold 243,735 at avg $53.82
$13.1M
36% of stake
Sep 15 – 1710b5-1 plan
Peter Heerma
EVP, Chief Commercial Officer · sold 283,189 at avg $63.06
$17.9M
71% of stake
Sep 15 – 1710b5-1 plan
Eric M Dube
Chief Executive Officer · sold 400,000 at avg $63.48
$25.4M
48% of stake
Sep 15 – 1610b5-1 plan
William E. Rote
Chief Research Officer · sold 209,048 at avg $62.83
$13.1M
68% of stake
Sep 1510b5-1 plan
Christopher R. Cline
Chief Financial Officer · sold 50,508 at avg $62.34
$3.15M
37% of stake
Sep 1510b5-1 plan
Jula Inrig
EVP, Head of R&D & CMO · sold 44,674 at avg $62.34
$2.79M
31% of stake
Sep 1510b5-1 plan
Sandra Calvin
SVP, Chief Accounting Officer · sold 5,375 at avg $62.33
335K
11% of stake
Sep 1510b5-1 plan
Elizabeth E Reed
Chief Legal Officer and GC · sold 37,500 at avg $62.34
$2.34M
26% of stake
Sep 1010b5-1 plan
Jeffrey A Meckler
Director · sold 20,000 at avg $67.30
$1.35M
18% of stake
Sep 2No plan
Christopher R. Cline
Chief Financial Officer · sold 642 at $66.37
43K
0.5% of stake
Aug 17 – 1810b5-1 plan
Gary A Lyons
Director · sold 10,000 at avg $63.29
633K
14% of stake
Jun 1210b5-1 plan
Roy D. Baynes
Director · sold 4,500 at $50.00
225K
9.8% of stake
Jun 1210b5-1 plan
Timothy Coughlin
Director · sold 10,000 at $50.07
501K
15% of stake
May 1510b5-1 plan
Timothy Coughlin
Director · sold 3,250 at $43.49
141K
5.9% of stake
May 5 – 610b5-1 plan
Christopher R. Cline
Chief Financial Officer · sold 2,491 at avg $46.31
115K
2.1% of stake
May 4 – 610b5-1 plan
Jula Inrig
Chief Medical Officer · sold 22,485 at avg $45.15
$1.02M
17% of stake
May 610b5-1 plan
Eric M Dube
Chief Executive Officer · sold 22,500 at $43.95
989K
4.9% of stake
May 610b5-1 plan
William E. Rote
Chief Research Officer · sold 2,763 at $43.95
121K
2.3% of stake
May 4 – 610b5-1 plan
Elizabeth E Reed
Chief Legal Officer and GC · sold 24,250 at avg $45.06
$1.09M
19% of stake
May 5No plan
Peter Heerma
Chief Commercial Officer · sold 2,174 at $46.65
101K
1.5% of stake
May 510b5-1 plan
Roy D. Baynes
Director · sold 4,500 at $46.65
210K
11% of stake
May 410b5-1 plan
Jeffrey A Meckler
Director · sold 8,000 at $45.00
360K
8.4% of stake
May 110b5-1 plan
Roy D. Baynes
Director · sold 9,750 at $44.22
431K
21% of stake
Apr 2210b5-1 plan
William E. Rote
Chief Research Officer · sold 9,100 at $39.09
356K
7.4% of stake
Apr 13 – 1510b5-1 plan
Christopher R. Cline
Chief Financial Officer · sold 8,327 at avg $41.91
349K
6.6% of stake
Apr 14 – 1510b5-1 plan
Jula Inrig
Chief Medical Officer · sold 8,233 at avg $42.01
346K
6.9% of stake
Apr 1510b5-1 plan
Eric M Dube
Chief Executive Officer · sold 64,000 at avg $41.09
$2.63M
13% of stake
Apr 14 – 1510b5-1 plan
Elizabeth E Reed
Chief Legal Officer and GC · sold 51,500 at avg $41.29
$2.13M
33% of stake
Apr 1410b5-1 plan
Sandra Calvin
SVP, Chief Accounting Officer · sold 21,977 at $41.07
903K
34% of stake
Apr 1410b5-1 plan
Roy D. Baynes
Director · sold 32,750 at avg $41.29
$1.35M
47% of stake
Apr 1410b5-1 plan
Gary A Lyons
Director · sold 8,000 at $41.07
329K
12% of stake
Apr 14No plan
Peter Heerma
Chief Commercial Officer · sold 7,215 at $41.93
303K
4.9% of stake
Apr 610b5-1 plan
Roy D. Baynes
Director · sold 10,000 at $33.00
330K
21% of stake
Apr 110b5-1 plan
Eric M Dube
Chief Executive Officer · sold 60,000 at avg $30.93
$1.86M
12% of stake
Apr 110b5-1 plan
Elizabeth E Reed
Chief Legal Officer and GC · sold 10,000 at $30.00
300K
8.7% of stake
Mar 1610b5-1 plan
Elizabeth E Reed
Chief Legal Officer and GC · sold 10,000 at $28.09
281K
8.7% of stake
Feb 2010b5-1 plan
Eric M Dube
Chief Executive Officer · sold 60,000 at $30.10
$1.81M
12% of stake
Feb 1710b5-1 plan
Elizabeth E Reed
Chief Legal Officer and GC · sold 10,000 at avg $27.83
278K
8.7% of stake
Feb 410b5-1 plan
Christopher R. Cline
Chief Financial Officer · sold 1,745 at avg $32.19
56K
1.5% of stake
Feb 410b5-1 plan
Jula Inrig
Chief Medical Officer · sold 1,779 at avg $32.21
57K
1.7% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TVTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with TVTX

CompareIntrinsic value

FOLDAmicus Therapeutics, Inc.

No recent price45

ARWRArrowhead Pharmaceuticals Inc.

$61.65+3.56%40

MIRMMirum Pharmaceuticals Inc.

$95.00+9.16%30

NRIXNurix Therapeutics Inc.

$15.95-38.23%84

CPRXCatalyst Pharmaceuticals Inc.

No recent price73

OPKOpko Health Inc.

$1.77+2.91%25

RAREUltragenyx Pharmaceutical Inc.

$17.16+3.19%40

AMPHAmphastar Pharmaceuticals Inc.

$28.02+3.32%60

Held by ETFs

TVTX is in 73 US ETFs. The largest of them, with TVTX's weight in each:

Spot a number that looks wrong? Check it in TVTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TVTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.